Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 691751
Drug: Placebo

First Posted Date: 2014-05-28

Last Posted Date: 2016-02-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02148107

Locations: 🇩🇪
1334.2.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Xentuzumab, low dose, every week (qw)
Drug: Xentuzumab, middle dose, qw
Drug: Xentuzumab, high dose, qw

First Posted Date: 2014-05-23

Last Posted Date: 2023-08-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 21

Registration Number: NCT02145741

Locations: 🇯🇵
National Cancer Center Hospital East, Chiba, Kashiwa, Japan

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: linagliptin

First Posted Date: 2014-05-16

Last Posted Date: 2017-02-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 166613

Registration Number: NCT02140645

Locations: 🇺🇸
Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States

Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2014-05-14

Last Posted Date: 2015-10-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 615067

Registration Number: NCT02138097

Locations: 🇺🇸
1218.161.1 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: BI 695501
Drug: US-licensed Humira®

First Posted Date: 2014-05-13

Last Posted Date: 2018-01-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 645

Registration Number: NCT02137226

Locations: 🇺🇸
North MS Medical Clinics, Incorporated, Tupelo, Mississippi, United States
🇺🇸
Glacier View Research Institute, Kalispell, Montana, United States
🇺🇸
Accurate Clinical Research, Inc., Lincoln, Nebraska, United States

and more 128 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: BI 639667
Drug: Placebo

First Posted Date: 2014-05-08

Last Posted Date: 2014-07-15

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02133482

Long-term Observation PMS for Afatinib

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Afatinib dimaleate

First Posted Date: 2014-05-06

Last Posted Date: 2018-09-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1605

Registration Number: NCT02131259

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site 145, Adachi Tokyo, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 47, Akita Akita, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 44, Akita Akita, Japan

and more 429 locations

LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Phase 3

Terminated

Conditions: Head and Neck Neoplasms

Interventions: Drug: Afatinib
Drug: Placebo

First Posted Date: 2014-05-06

Last Posted Date: 2019-03-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02131155

Locations: 🇨🇳
1200.162.86013 Boehringer Ingelheim Investigational Site, Jinan, China
🇨🇳
1200.162.86007 Boehringer Ingelheim Investigational Site, Chengdu, China
🇰🇷
1200.162.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

and more 13 locations

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: T80/A5/H12.5 mg FDC tablet
Drug: Amlodipine 5mg capsule
Drug: T80/H12.5 mg FDC tablet

First Posted Date: 2014-05-02

Last Posted Date: 2017-04-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT02129192

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Tokyo, Hachioji, Japan

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee

Phase 1

Completed

Conditions: Osteoarthritis

Interventions: Drug: Placebo to BI 1026706
Drug: BI 1026706

First Posted Date: 2014-04-30

Last Posted Date: 2019-03-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 58

Registration Number: NCT02126826

Locations: 🇩🇪
1320.2.2 Boehringer Ingelheim Investigational Site, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy